ABL Bio and NEOK Bio Advance First-in-Class Bispecific ADC ABL206 to Phase 1 Clinical Trial
核心洞察
ABL Bio (搜索) and NEOK Bio (搜索) received FDA approval to proceed with Phase 1 clinical trials of ABL206, a first-in-class bispecific antibody-drug conjugate targeting ROR1 and B7-H3 (搜索) for solid tumors (搜索).
ABL206 demonstrated improved efficacy and safety compared to conventional monospecific antibody ADCs in preclinical studies, representing a significant advancement in next-generation ADC technology.
NEOK Bio (搜索) plans to initiate Phase 1 trials for both ABL206 and ABL209 (搜索) in the first half of 2025, with initial clinical data expected in 2027.
ABL Bio (搜索) and its U.S.-based subsidiary NEOK Bio (搜索) have achieved a significant milestone in next-generation antibody-drug conjugate development, receiving FDA approval to proceed with Phase 1 clinical trials of ABL206 (NEOK001), a first-in-class bispecific ADC targeting solid tumors (搜索).
The FDA approved the Investigational New Drug (IND) application on December 16, following submission on December 19 (local time), marking the entry of ABL Bio (搜索)'s bispecific ADC platform into clinical development.
Novel Bispecific ADC Design Shows Preclinical Promise
ABL206 represents a breakthrough in ADC technology, featuring a bispecific antibody that simultaneously targets ROR1 and B7-H3 (搜索), conjugated with a topoisomerase I (搜索) inhibitor. This dual-targeting approach demonstrated improved efficacy and safety compared to conventional monospecific antibody ADCs in preclinical studies.
The compound is designed as an innovative treatment for patients with various solid tumors (搜索), addressing high unmet medical needs in oncology. ABL Bio (搜索) developed ABL206 based on its proprietary bispecific antibody technology and extensive experience in monospecific antibody ADC development.
Strategic Clinical Development Partnership
NEOK Bio (搜索), a U.S.-based biotech company established by ABL Bio (搜索) and specializing in clinical development of bispecific antibody ADCs, will lead the overall development starting from the Phase 1 clinical trial. The company holds global development and commercialization rights for both ABL206 and another bispecific ADC candidate, ABL209 (搜索) (NEOK002).
The strategic partnership leverages ABL Bio (搜索)'s preclinical research expertise while positioning NEOK Bio (搜索) to execute systematic clinical development plans in the U.S. market.
Accelerated Timeline for Next-Generation Pipeline
NEOK Bio (搜索) plans to submit an IND application for ABL209 (搜索)'s Phase 1 clinical trial in early 2025. The company aims to initiate Phase 1 clinical trials for both candidates in the first half of 2025, with initial clinical data expected in 2027.
"With the IND submission for the Phase 1 clinical trial of ABL206, the development of bispecific antibody ADCs by ABL Bio (搜索) and NEOK Bio (搜索) has officially begun," stated Lee Sanghoon, CEO of ABL Bio. "Since announcing our next-generation ADC development plan last year, we have devoted all our efforts to quickly enter the bispecific ADC market, and as a result, we were able to complete clinical preparations on schedule."
Expanding Next-Generation ADC Platform
ABL Bio (搜索) continues advancing its comprehensive next-generation ADC platform, actively conducting research and development on various technologies including bispecific ADCs and dual payload ADCs. This diversified approach positions the company at the forefront of ADC innovation.
Mayank Gandhi, CEO of NEOK Bio (搜索), emphasized the significance of this achievement: "The IND submission for ABL206 marks a significant milestone in NEOK Bio's transition to a clinical-stage company and is the result of close collaboration between ABL Bio (搜索) and NEOK Bio. We are excited to move forward with a systematic clinical development plan for ABL206, and we will continue to demonstrate the differentiated value of bispecific ADCs for patients with solid tumors (搜索)."